BioSpace News Archive

Incyte announced new research detailing the development and mechanism of action of INCA033989, an Incyte-discovered, investigational novel anti-mutant calreticulin -targeted monoclonal antibody.

Ascentage Pharma announced that it has released preliminary results of olverembatinib in patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, in an Oral Presentation at the American Society of Hematology 64th Annual Meeting and Exposition, marking the first data readout from the US study.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, announced positive updated clinical data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis.

Sana Biotechnology, Inc. shared data in six presentations at the 64th American Society of Hematology Annual Meeting and Exposition, taking place from Saturday, December 10 to Tuesday, December 13, 2022 in New Orleans, LA, which highlighted further progress with key technologies supporting Sana’s ex vivo allogeneic CAR T cell programs and in vivo platform.

AbbVie announced data from multiple clinical trials evaluating epcoritamab, an investigational subcutaneous bispecific antibody, alone or in combination for the treatment of patients with relapsed/refractory follicular lymphoma, previously untreated FL, R/R diffuse large B-cell lymphoma, as well as Richter’s syndrome at the 64th American Society of Hematology Annual Meeting.

GSK plc announced new 48-week data from the MOMENTUM phase III trial that showed a majority of patients treated with investigational momelotinib maintained their responses across key clinical measures including Total Symptom Score, Transfusion Independence rate, and Splenic Response Rate in myelofibrosis patients previously treated with an approved Janus kinase inhibitor.

Genmab A/S announced the results from multiple clinical trials evaluating epcoritamab, an investigational subcutaneous bispecific antibody.

CTI BioPharma Corp. announced an oral presentation and two poster presentations from the Company’s pacritinib program at the 64th American Society of Hematology Annual Meeting and Exposition, taking place in New Orleans, Louisiana and virtually December 10-13, 2022.

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases.

Aptose Biosciences Inc. provided a clinical update of its lead oral myeloid kinome inhibitor, tuspetinib, as responses continue to emerge from a Phase 1/2 trial, and from its oral, dual lymphoid and myeloid kinase inhibitor, luxeptinib in an ongoing Phase 1a/b trial.